Clinical Trials Using FMS Inhibitor JNJ-40346527

Clinical trials are research studies that involve people. The clinical trials on this list are studying FMS Inhibitor JNJ-40346527. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-2 of 2
  • FMS Inhibitor JNJ-40346527 in Treating Participants with Relapsed or Refractory Acute Myeloid Leukemia

    This phase II trial studies how well FMS inhibitor JNJ-40346527 works in treating participants with acute myeloid leukemia that has come back or does not respond to treatment. FMS inhibitor JNJ-40346527 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
    Location: 2 locations

  • Daratumumab or FMS Inhibitor JNJ-40346527 before Surgery in Treating Patients with High-Risk, Resectable Localized or Locally Advanced Prostate Cancer

    This phase I trial studies the side effects of daratumumab or FMS inhibitor JNJ-40346527 before surgery in treating patients with high-risk prostate cancer that can be removed by surgery and has not spread to other parts of the body or has spread to nearby tissue or lymph nodes. Immunotherapy with monoclonal antibodies, such as daratumumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spreadFMS inhibitor JNJ-40346527 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving daratumumab or FMS inhibitor JNJ-40346527 before surgery may work better in treating patients with prostate cancer.
    Location: M D Anderson Cancer Center, Houston, Texas